|

Sacituzumab Tirumotecan and Toripalimab Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University1

Indications

  • Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma1
  • Cancer1

Other1 trial

Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.